SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-117735
Filing Date
2023-11-14
Accepted
2023-11-14 08:35:57
Documents
15
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330650d1_8k.htm   iXBRL 8-K 28481
2 EXHIBIT 99.1 tm2330650d1_ex99-1.htm EX-99.1 117717
7 GRAPHIC tm2330650d1_ex99-1img001.jpg GRAPHIC 1688
  Complete submission text file 0001104659-23-117735.txt   385777

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20231113.xsd EX-101.SCH 3303
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20231113_def.xml EX-101.DEF 26897
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20231113_lab.xml EX-101.LAB 36508
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20231113_pre.xml EX-101.PRE 25521
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2330650d1_8k_htm.xml XML 4906
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 231401794
SIC: 2834 Pharmaceutical Preparations